Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments

• Verfasst von: Keilholz, Ulrich [VerfasserIn]
• Verfasst von: Schadendorf, Dirk [VerfasserIn]
• Titel: Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments
• Titelzusatz: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin
• Verf.angabe: U. Keilholz, P. Martus, C.J.A. Punt, W. Kruit, G. Mooser, D. Schadendorf, D. Liénard, R. Dummer, J. Koller, C. Voit, A.M.M. Eggermont
• E-Jahr: 2002
• Jahr: 24 April 2002
• Umfang: 11 S.
• Fussnoten: Gesehen am 17.11.2020
• Titel Quelle: Enthalten in: European journal of cancer
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1965
• Jahr Quelle: 2002
• Band/Heft Quelle: 38(2002), 11, Seite 1501-1511
• ISSN Quelle: 1879-0852
• DOI: doi:10.1016/S0959-8049(02)00123-5
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cytokines
• Sach-SW: IL2
• Sach-SW: Melanoma
• Sach-SW: Prognostic factors
• K10plus-PPN: 1738907775

Abstract

The aim of this study was to define prognostic factors for survival, and especially for long-term survival in a mature data-set of patients with stage IV melanoma treated within a randomised trial of cytokine-based protocols. Long-term follow-up data on patients enrolled into a European Organization for Research and Treatment of Cancer (EORTC) trial comparing interferon-α (IFNα) plus interleukin-2 (IL-2) with or without cisplatin were collected. Univariate and multivariate Cox regression analyses wereperformed to define prognostic factors for survival. The characteristics of patients alive at 2 and 5 years after randomisation were compared with the entire cohort using the χ2 test. The minimum potential follow-up of the 131 evaluable patients was 5 years. 18 patients (14%) were alive 2 years after randomisation, and 11 (8%) 5 years after randomisation. Pretreatment performance status (PS), serum lactate dehydrogenase (LDH) and tumour mass were significant predictors for survival, whereas site of metastases and number of sites were non-significant. PS and LDH were the only independent prognostic factors. All except 1 patient alive at 2 and 5 years had a pretreatment PS of 100%, and only three long-term survivors had elevated pretreatment LDH. There was no association between the site of metastases and long-term survival. Response to treatment was a major predictor for long-term survival, whereas addition of cisplatin did not impact upon overall survival probability or on long-term survival. The probability of long-term survival in stage IV melanoma patients after IL-2-based treatments is governed by pretreatment PS, serum LDH and response to treatment. Site of metastases, the basis for the M-subcategories of the new AJCC staging system, was not informative in this study.